Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-10-08
|
Opdivo® (nivolumab) |
platinum-refractory patients with metastatic urothelial carcinoma |
|
BMS (USA - NY) |
Cancer - Oncology |
2016-10-08
|
Yervoy® (ipilimumab) |
stage III melanoma patients at high risk of recurrence following complete surgical resection |
3 |
BMS (USA - NY) |
Cancer - Oncology - Rare diseases |
2016-10-08
|
combination of dabrafenib and trametinib |
metastatic melanoma with BRAF V600 mutations |
3 |
Novartis (Switzerland) |
Cancer - Oncology |
2016-10-07
|
ASG-15ME |
previously treated metastatic urothelial cancer |
1 |
Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan) Agensys, an affiliate of Astellas (Japan) |
Cancer - Oncology |
2016-10-07
|
ABO-201 (AAV-CLN3) |
Batten disease |
preclinical |
Abeona Therapeutics (USA - NY) |
Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases |
2016-10-06
|
CHS-0214 (investigational etanercept biosimilar) |
rheumatoid arthritis |
1 |
Coherus Biosciences (USA - CA) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-10-06
|
daratumumab in combination with lenalidomide and dexamethasone |
multiple myeloma |
3 |
Janssen Research & Development, a J&J company (USA - NJ) |
Cancer - Oncology |
2016-10-06
|
TOP1288 |
ulcerative colitis |
2a |
Topivert Pharma (UK) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-10-06
|
Translarna™ (ataluren) |
non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD) |
preclinical |
PTC Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases |
2016-10-06
|
axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) and atezolizumab |
refractory diffuse large B cell lymphoma (DLBCL) |
1-2a |
Kite Pharma (USA - CA) Genentech, a member of Roche Group (USA - CA - Switzerland) |
Cancer - Oncology |
2016-10-05
|
|
|
preclinical |
Transgene (France) |
Cancer - Oncology |
2016-10-05
|
Yeliva™ (ABC294640) |
hepatocellular carcinoma |
2 |
Redhill Biopharma (Israel) Apogee Biotechnology (USA - PA) |
Cancer - Oncology |
2016-10-05
|
ALN-TTRsc - revusiran |
TTR-mediated amyloidosis (ATTR), TTR cardiac amyloidosis |
3 |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Genetic diseases |
2016-10-05
|
SCY-078 ((1,3)-ß-D-glucan synthesis inhibitor) |
invasive candidiasis |
2 |
Scynexis (USA - NJ) |
Infectious diseases |
2016-10-04
|
Precision Promise |
pancreatic cancer |
|
Pancreatic Cancer Action Network (USA) |
Cancer - Oncology |
2016-10-04
|
Translarna™ (ataluren) |
|
preclinical |
PTC Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases |
2016-10-03
|
|
nonvalvular atrial fibrillation in elderly patients |
registry study |
Daiichi Sankyo (Japan) |
Cardiovascular diseases |
2016-10-03
|
Cimzia® (certolizumab pegol) |
moderate-to-severe chronic plaque psoriasis |
3 |
UCB (Belgium) |
Autoimmune diseases - Dermatological diseases |
2016-10-01
|
Dupixent® (dupilumab) |
moderate-to-severe atopic dermatitis |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Dermatological diseases - Inflammatory diseases |
2016-10-01
|
tildrakizumab |
moderate-to-severe plaque psoriasis |
3 |
Merck&Co (USA - NJ) Sun Pharmaceuticals (India) |
Autoimmune diseases - Dermatological diseases - Inflammatory diseases |